Gelonghui November 16丨Chengyi Pharmaceutical (603811.SH) said at the performance briefing that during the “14th Five-Year Plan” period, Chenyi Pharmaceutical will closely focus on the three development directions of “marine medicine, biomedicine, and traditional Chinese medicine” and the “10 billion market value, 100 year enterprise” goal, focusing on planning the “two strengths and one big” project of Asia's largest annual production of 2,000 tons of aminose APIs and 1,000 tons of pharmaceutical-grade high-purity EPA, focusing on the big health industry and striving to achieve the entire process, full product category and chain layout from food to health products to pharmaceuticals Strive to seize the strategic high ground and empower the enterprise with new value, Realize corporate groupings and high-quality development.
诚意药业(603811.SH)：重点谋划亚洲最大年产2000吨氨糖原料药和1000吨药用级高纯度EPA“两强一大”项目
Chengyi Pharmaceutical (603811.SH): Focusing on planning Asia's largest annual production of 2,000 tons of ammonia sugar APIs and 1,000 tons of pharmaceutical-grade high-purity EPA “two strengths and one big” project
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.